Vivos Therapeutics Inc. has announced that it will hold its 2025 Annual Meeting of Stockholders on November 4, 2025. The meeting will be conducted virtually via a live webcast. Stockholders will vote on several proposals, including the election of directors, approval of an amendment to the 2024 Omnibus Equity Incentive Plan, and the ratification of the appointment of Baker Tilly US, LLP (as successor to Moss Adams LLP) as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-015837), on September 29, 2025, and is solely responsible for the information contained therein.